<DOC>
	<DOCNO>NCT01846715</DOCNO>
	<brief_summary>The primary purpose study assess safety optimal delivery Neo-Kidney Augment ( NKA ) implant one site recipient kidney . NKA make expand autologous , homologous , select renal cell ( SRC ) obtain patient 's kidney biopsy .</brief_summary>
	<brief_title>Study Autologous Neo-Kidney Augment Patients With Chronic Kidney Disease</brief_title>
	<detailed_description>Therapeutic intervention NKA intend delay need renal replacement therapy ( dialysis transplant ) time , inevitable patient CKD . NKA compose autologous , homologous select renal cell ( SRC ) formulate Biomaterial ( gelatin-based hydrogel ) . SRC biologically active component NKA . Proof principle SRC biologically active component NKA establish multiple model CKD . Based nonclinical efficacy safety data , single NKA dose deliver patient FIH clinical trial . This dose provide minimum 1.5-fold safety margin dos deliver safely nonclinical study . In addition , dose demonstrate efficacy nonclinical disease model .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Male female subject , age 18 70 year date inform consent . 2 . Patients estimate Glomerular Filtration Rate 15 60 mL/min Screening due intrinsic `` medical '' renal disease ( nephropathy due type2 diabetes , nephrosclerosis chronic glomerulonephritis ) . 3 . Mean systolic blood pressure 105 160 mmHg , inclusive ; mean diastolic blood pressure must ≤90 mmHg . Patients blood pressure outside range prior implant , may implant approve Medical Monitor . 4 . Ongoing treatment angiotensin convert enzyme inhibitor and/or angiontensin receptor blocker , initiate least 6 week prior screen . 5 . Minimum 3 month medical history CKD progression assess laboratory value . 6 . Willing able refrain use NSAIDs ( include aspirin ) clopidogrel 10 day 10 day biopsy implant . 7 . Willing able cooperate aspect study . 8 . Willing able give sign informed consent . 1 . Type 1 diabetes mellitus ( DM ) . 2 . History renal transplant . 3 . HbA1c ≥ 104 mmol/mol IFCC Screening . 4 . BMI &lt; 18.5 kg/m2 &gt; 35 kg/m2 Screening . 5 . Abnormal coagulation status measure APTT , INR , fibrinogen and/or platelet count . 6 . Ineligible MRI renal scintigraphy ( e.g . due hypersensitivity allergy ) study base Karolinska University Hospital guideline . 7 . Clinically significant infection require parenteral antibiotic within 6 week biopsy implantation . 8 . CKD due polycystic kidney disease , renal structural abnormality , myeloma kidney , history nephroblastoma , poststreptococcal glomerulonephritis , pre postrenal component CKD , genetically base renal disease ( e.g . Podocin mutation , renal agenesis ) . 9 . Patients small ( &lt; 10 cm ) kidneys one kidney ; patient history highly echogenic kidney . Patients average width kidney cortex &lt; 1.0 cm estimate MRI . Patients whose left kidney would acceptable biopsy/implant assess Investigator base result screen procedure . 10 . Female subject pregnant , lactate ( breast feed ) plan pregnancy course study , child bear potential use highly effective method birth control ( include sexual abstinence ) . A highly effective method birth control define one result low failure rate ( i.e . le 1 percent per year ) use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence , vasectomized partner . Subjects must willing continue birth control method throughout course study . 11 . History cancer within past 5 year ( exclude nonmelanoma skin cancer carcinoma situ cervix ) condition highly likely transform malignancy course study . 12 . Life expectancy le 2 year . 13 . Any contraindication know anaphylactic severe systemic reaction either human blood product material animal ( bovine , porcine ) origin anesthetic agent . 14 . Positive result follow ( per Commission Directive 2006/17/EC ) Screening Biopsy : 1 . Viral Nucleic Acid Testing : Human Immunodeficiency Virus ( HIV ) 1 2 RNA , Hepatitis B Virus ( HBV ) DNA , Hepatitis C Virus ( HCV ) RNA 2 . Viral Protein Testing : HBV surface antigen ( HBsAg ) 3 . Viral Antibody Testing : AntiHIV 1 2 , AntiHBV core antigen ( Anti HBc ) , AntiHCV antibody . 4 . Confirmed active infection Treponema pallidum . 15 . Subjects active tuberculosis ( TB ) require treatment past 3 year . 16 . Immunocompromised subject patient receive immunosuppressive agent ( include patient treat chronic glomerulonephritis ) within 3 month biopsy . [ Note : inhaled corticosteroid chronic lowdose corticosteroid [ ≤ 7.5mg per day ] permit brief pulsed corticosteroid intermittent symptom ( e.g . asthma ) . ] 17 . Subjects uncontrolled diabetes ( define metabolically unstable PI ) , incapacitate cardiac and/or pulmonary disorder . 18 . History active alcohol and/or drug abuse investigator 's assessment would impair subject 's ability comply protocol . 19 . Subjects albumin value &lt; 25 g/L , albumin/creatinine ratio great 3500mg/g Screening prior Biopsy . 20 . Patients clinically significant hepatic disease ( ALAT ASAT &gt; 5.0 x ULN ) Screening . 21 . Patients bleed disorder patient take Coumarins ( e.g. , Warfarin ) . 22 . Any circumstance investigator deem participation study subject 's best interest . 23 . Use investigational product ( drug , biologic , device ) within 5 halflives ( drug , biologic ) 3 month , whichever long , without receive prior write consent Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Kidney disease</keyword>
	<keyword>Renal insufficiency</keyword>
	<keyword>CKD</keyword>
	<keyword>Autologous cell therapy</keyword>
</DOC>